Retatrutide is hypothesized to act as a triple receptor agonist in preclinical models, interacting with pathways commonly associated with glucagon, GLP-1 (glucagon-like peptide-1), and GIP (glucose-dependent insulinotropic polypeptide)
Similarly, the SURMOUNT trials for weight management did not report elevated rates of sore throat compared to placebo
Lifestyle is still key: Patients will benefit most if they combine the medication with healthy eating and exercise
Healthcare professionals contribute to this knowledge base by maintaining accurate records of patient responses
What Phase 3 Must Answer Phase 3 trials must enroll thousands of diverse participants and track them for years
Effectively Dealing with Nausea for GLP-1 Medication Users There is no one, universal experience for patients who use GLP-1 medications, and each patient will have different side effects to varying degrees of severity